A compound according to Formula I: wherein, X is O or NR 4; n is 0, 1, or 2; Het is 5 membered monocyclic heteroaryl comprising one, two or three heteroatoms independently selected from N, O, and S; R 1 is -OR 5 or -NR 6a R 6b; each R 2 is independently selected from - -O-R 7, - C 1-6 alkyl optionally substituted with one or more independently selected halo, - C 3-6 cycloalkyl, - -C(=O)-NR 8a R 8b, - 4-6 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, and - 4-6 membered monocyclic heterocycloalkenyl comprising one double bond and further comprising one, or two heteroatoms independently selected from N, O, and S; R 3a and R 3b are independently H or C 1-3 alkyl optionally substituted with one or more independently selected halo; R 4 is C 1-3 alkyl optionally substituted with one or more F; R 5 is H or C 1-4 alkyl optionally substituted with one or more independently selected -C(=O)-NR 9a R 9b or -O-C(=O)-C 1-6 alkyl; R 6a and R 6b are independently H, -S(=O) 2 -C 1-4 alkyl, or -S(=O) 2 -C 3-6 cycloalkyl; each R 7 is independently selected from - C 1-6 alkyl optionally substituted with one or more independently selected halo or C 1-4 alkoxy, and - 4-6 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S; R 8a and R 8b are independently H, C 1-4 alkyl, or phenyl; and R 9a and R 9b are independently H or C 1-4 alkyl; or a pharmaceutically acceptable salt, solvate, or salt of a solvate thereof. X is O or NR 4; n is 0, 1, or 2; Het is 5 membered monocyclic heteroaryl comprising one, two or three heteroatoms independently selected from N, O, and S; R 1 is -OR 5 or -NR 6a R 6b; each R 2 is independently selected from - -O-R 7, - C 1-6 alkyl optionally substituted with one or more independently selected halo, - C 3-6 cycloalkyl, - -C(=O)-NR 8a R 8b, - 4-6 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, and - 4-6 membered monocyclic heterocycloalkenyl comprising one double bond and further comprising one, or two heteroatoms independently selected from N, O, and S; - -O-R 7, - C 1-6 alkyl optionally substituted with one or more independently selected halo, - C 3-6 cycloalkyl, - -C(=O)-NR 8a R 8b, - 4-6 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S, and - 4-6 membered monocyclic heterocycloalkenyl comprising one double bond and further comprising one, or two heteroatoms independently selected from N, O, and S; R 3a and R 3b are independently H or C 1-3 alkyl optionally substituted with one or more independently selected halo; R 4 is C 1-3 alkyl optionally substituted with one or more F; R 5 is H or C 1-4 alkyl optionally substituted with one or more independently selected -C(=O)-NR 9a R 9b or -O-C(=O)-C 1-6 alkyl; R 6a and R 6b are independently H, -S(=O) 2 -C 1-4 alkyl, or -S(=O) 2 -C 3-6 cycloalkyl; each R 7 is independently selected from - C 1-6 alkyl optionally substituted with one or more independently selected halo or C 1-4 alkoxy, and - 4-6 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S; - C 1-6 alkyl optionally substituted with one or more independently selected halo or C 1-4 alkoxy, and - 4-6 membered monocyclic heterocycloalkyl comprising one, two or three heteroatoms independently selected from N, O, and S; R 8a and R 8b are independently H, C 1-4 alkyl, or phenyl; and R 9a and R 9b are independently H or C 1-4 alkyl; or a pharmaceutically acceptable salt, solvate, or salt of a solvate thereof.